Cardiac Toxicity
37
5
6
18
Key Insights
Highlights
Success Rate
82% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
10.8%
4 terminated out of 37 trials
81.8%
-4.7% vs benchmark
24%
9 trials in Phase 3/4
22%
4 of 18 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 18 completed trials
Clinical Trials (37)
The STOP-MED CTRCD Trial
Evaluation of Impedance Cardiography for Assessing Hemodynamic Shifts in Patients With LA-NSCLC During Treatment.
Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted
Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)
Cardiovascular Health in Adult Patients With Cancer Exposed to Cardiotoxic Therapies
Translating ECHOS2 Into an mHealth Platform
COr Loco-regional Advanced Lung Cancer Treated With Chemo-radiotherapy (COLA)
BreAst Cancer and Cardiotoxicity Induced by RAdioTherapy: the BACCARAT Study
Cardiac Magnetic Resonance Imaging in Patients With Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin
MRI in Detecting Heart Damage in Patients With Cancer Receiving Chemotherapy With Exercise Capacity Addendum
Cardiovascular Effects of Intrathecal Hyperbaric Prilocaine or Bupivacaine in Surgery Under Spinal Anesthesia
Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery
Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain
Cardiotoxicity of Targeted Therapy for HER-2 Positive Breast Cancer Patients at High Altitude
Radiation-induced Cardiac Toxicity After Non-small Cell Lung Cancer Radiotherapy
Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients
Effects of Anti-VEGF Targeted Drugs on Patients' Blood Pressure and Endothelial Function
Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab
Exercise Response After Revalidation in Cancer Patients
Association Between Telomere Length and Cardiac Dysfunction